27th February 2019 – Can-Fite BioPharma
Limited issued an announcement, which is summarized as follows:
*Can-Fite has already entered into three
partnership agreements in Asia providing for upfront payments and potential
aggregate milestone payments of up to $85M for its drug candidates
*One-on-One meetings planned with over 20 potential
BioPharma Limited announced the Company’s VP of Business Development, Sari
Fishman will participate in the Bio Asia International Conference in Tokyo,
Japan on March 5th and 6th, 2019.
current pharma partnerships in Asia include Kwang Dong in Korea for
Piclidenoson, Chong Kun Dang in Korea for Namodenoson, and CMS in China for
Piclidenoson and Namodenoson. The Company sees substantial additional
partnership opportunities in Asia.